1. Scrip
  2. >>Business
  3. >>Deals

AstraZeneca Buys Into In Vivo Cell Therapy Potential With EsoBiotec

 
• By Andrew McConaghie

The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.

Astrazeneca
• Source: Shutterstock

AstraZeneca is adding to its cell therapy portfolio again, this time buying EsoBiotec, a biotech with an early-stage in vivo CAR-T technology, in the hope of becoming a pioneer in a transformative field.

Belgium-based EsoBiotec’s approach offers a novel off-the-shelf alternative to CAR-Ts, enabling cell therapies to be administered through a simple intravenous injection and without the need for immune cell depletion

Key Takeaways
  • AstraZeneca is buying EsoBiotec for its novel in vivo lentiviral nanobody which reprograms T-cells in the body

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Advanced Therapies